InvOpps GP IV, L.L.C. 4

Accession 0000899243-19-026771

CIK 0001720725other

Filed

Nov 5, 7:00 PM ET

Accepted

Nov 6, 4:30 PM ET

Size

21.6 KB

Accession

0000899243-19-026771

Form 4

Period: 2019-11-04

Director10% Owner

Transactions

Conversion
Common Stock, par value $0.001 per share
2019-11-04+1,230,050→ 1,230,050 total(indirect: See Footnotes)
Conversion
Series B Convertible Preferred Stock
2019-11-04−609,965→ 0 total(indirect: See Footnotes)
→ Common Stock, par value $0.001 per share (609,965 underlying)
Purchase
Common Stock, par value $0.001 per share
2019-11-04$16.00/sh+501,375$8,022,000→ 1,731,425 total(indirect: See Footnotes)
Conversion
Series B Convertible Preferred Stock
2019-11-04−1,230,050→ 0 total(indirect: See Footnotes)
→ Common Stock, par value $0.001 per share (1,230,050 underlying)
Conversion
Common Stock, par value $0.001 per share
2019-11-04+609,965→ 609,965 total(indirect: See Footnotes)
Purchase
Common Stock, par value $0.001 per share
2019-11-04$16.00/sh+248,625$3,978,000→ 858,590 total(indirect: See Footnotes)

Director10% Owner

Transactions

Conversion
Common Stock, par value $0.001 per share
2019-11-04+609,965→ 609,965 total(indirect: See Footnotes)
Conversion
Common Stock, par value $0.001 per share
2019-11-04+1,230,050→ 1,230,050 total(indirect: See Footnotes)
Purchase
Common Stock, par value $0.001 per share
2019-11-04$16.00/sh+501,375$8,022,000→ 1,731,425 total(indirect: See Footnotes)
Conversion
Series B Convertible Preferred Stock
2019-11-04−1,230,050→ 0 total(indirect: See Footnotes)
→ Common Stock, par value $0.001 per share (1,230,050 underlying)
Purchase
Common Stock, par value $0.001 per share
2019-11-04$16.00/sh+248,625$3,978,000→ 858,590 total(indirect: See Footnotes)
Conversion
Series B Convertible Preferred Stock
2019-11-04−609,965→ 0 total(indirect: See Footnotes)
→ Common Stock, par value $0.001 per share (609,965 underlying)

Director10% Owner

Transactions

Conversion
Common Stock, par value $0.001 per share
2019-11-04+609,965→ 609,965 total(indirect: See Footnotes)
Conversion
Common Stock, par value $0.001 per share
2019-11-04+1,230,050→ 1,230,050 total(indirect: See Footnotes)
Purchase
Common Stock, par value $0.001 per share
2019-11-04$16.00/sh+248,625$3,978,000→ 858,590 total(indirect: See Footnotes)
Conversion
Series B Convertible Preferred Stock
2019-11-04−609,965→ 0 total(indirect: See Footnotes)
→ Common Stock, par value $0.001 per share (609,965 underlying)
Conversion
Series B Convertible Preferred Stock
2019-11-04−1,230,050→ 0 total(indirect: See Footnotes)
→ Common Stock, par value $0.001 per share (1,230,050 underlying)
Purchase
Common Stock, par value $0.001 per share
2019-11-04$16.00/sh+501,375$8,022,000→ 1,731,425 total(indirect: See Footnotes)

Director10% Owner

Transactions

Conversion
Common Stock, par value $0.001 per share
2019-11-04+609,965→ 609,965 total(indirect: See Footnotes)
Conversion
Common Stock, par value $0.001 per share
2019-11-04+1,230,050→ 1,230,050 total(indirect: See Footnotes)
Purchase
Common Stock, par value $0.001 per share
2019-11-04$16.00/sh+248,625$3,978,000→ 858,590 total(indirect: See Footnotes)
Purchase
Common Stock, par value $0.001 per share
2019-11-04$16.00/sh+501,375$8,022,000→ 1,731,425 total(indirect: See Footnotes)
Conversion
Series B Convertible Preferred Stock
2019-11-04−609,965→ 0 total(indirect: See Footnotes)
→ Common Stock, par value $0.001 per share (609,965 underlying)
Conversion
Series B Convertible Preferred Stock
2019-11-04−1,230,050→ 0 total(indirect: See Footnotes)
→ Common Stock, par value $0.001 per share (1,230,050 underlying)

Footnotes (5)

[F1]These shares of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's common stock (the "Common Stock"), on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Series B Convertible Preferred Stock had no expiration date.
[F2]Reflects securities directly held by InvOpps IV US, L.P. ("Invus IV US").
[F3]Reflects securities directly held by InvOpps IV, L.P. ("Invus IV").
[F4]InvOpps GP IV, L.L.C. ("InvOpps GP") is the sole general partner of each of Invus IV and Invus IV US. Sacha Lainovic is the managing member of InvOpps GP.
[F5]Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.

Documents

1 file

Oyster Point Pharma, Inc.

CIK 0001720725

Entity typeother

IncorporatedDE